Amygdala Neuroscience is a biotechnology company that is focused on developing treatments for anxiety and depression. The company's lead product candidate is a small molecule drug that targets the amygdala, a key brain region involved in the regulation of emotions. Amygdala Neuroscience was founded in 2018 by a team of scientists and entrepreneurs with expertise in neuroscience, drug discovery, and business development. The company is headquartered in Palo Alto, California.